MYGN Myriad Genetics, Inc. Stock Quote

MYGN [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-3.27	Insider Own	2.70%	Shs Outstand	75.00M	Perf Week	0.98%
Market Cap	2.22B	Forward P/E	83.60	EPS next Y	0.34	Insider Trans	-6.08%	Shs Float	73.40M	Perf Month	-8.99%
Income	-244.40M	PEG	-	EPS next Q	-0.14	Inst Own	-	Short Float	7.06%	Perf Quarter	15.87%
Sales	557.00M	P/S	3.98	EPS this Y	63.40%	Inst Trans	1.71%	Short Ratio	6.90	Perf Half Y	118.54%
Book/sh	11.75	P/B	2.45	EPS next Y	278.90%	ROA	-8.70%	Target Price	26.00	Perf Year	99.72%
Cash/sh	1.95	P/C	14.73	EPS next 5Y	8.10%	ROE	-13.50%	52W Range	10.54 - 33.97	Perf YTD	45.44%
Dividend	-	P/FCF	-	EPS past 5Y	-21.20%	ROI	-6.10%	52W High	-19.50%	Beta	1.61
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	-16.50%	Gross Margin	68.00%	52W Low	159.44%	ATR	1.66
Employees	2700	Current Ratio	2.70	Sales Q/Q	53.70%	Oper. Margin	-35.10%	RSI (14)	42.28	Volatility	4.92% 5.91%
Optionable	Yes	Debt/Eq	0.26	EPS Q/Q	-782.00%	Profit Margin	-22.20%	Rel Volume	0.44	Prev Close	28.76
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Feb 23 AMC	Payout	-	Avg Volume	750.74K	Price	27.34
Recom	3.10	SMA20	-6.90%	SMA50	-7.66%	SMA200	41.09%	Volume	205,875	Change	-4.92%

Sep-26-19

Downgrade

BofA/Merrill

Neutral → Underperform

$30 → $28

Aug-14-19

Downgrade

Piper Jaffray

Overweight → Neutral

$45 → $40

Aug-02-19

Upgrade

BofA/Merrill

Underperform → Neutral

Aug-01-19

Upgrade

Barclays

Underweight → Equal Weight

$18 → $40

Jul-29-19

Downgrade

Needham

Strong Buy → Hold

Jul-09-19

Downgrade

Cowen

Outperform → Market Perform

Mar-12-19

Reiterated

Needham

Strong Buy

$37 → $41

Jan-03-19

Initiated

Needham

Strong Buy

$36

Nov-30-18

Upgrade

Goldman

Sell → Neutral

Oct-10-18

Upgrade

Piper Jaffray

Neutral → Overweight

Jul-11-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Mar-21-18

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Jan-29-18

Initiated

Goldman

Sell

$32

Jan-22-18

Reiterated

Barclays

Equal Weight

$30 → $35

Jan-05-18

Initiated

BTIG Research

Buy

$41

Oct-02-17

Resumed

Leerink Partners

Mkt Perform

$31

Aug-09-17

Reiterated

Barclays

Equal Weight

$28 → $26

Feb-08-17

Upgrade

Ladenburg Thalmann

Sell → Neutral

Jan-18-17

Initiated

Deutsche Bank

Sell

$15

Oct-10-16

Downgrade

Ladenburg Thalmann

Neutral → Sell

Apr-14-21 10:38AM	Balaji Srinivasans Top 10 Investments, Portfolio and Ideas Insider Monkey
Apr-09-21 09:00AM	3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19 Zacks
Mar-31-21 08:00AM	Sera Prognostics Appoints Robert G. Harrison as Chief Information Officer GlobeNewswire
Mar-29-21 09:50AM	Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement Zacks
07:05AM	Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders GlobeNewswire
Mar-25-21 11:30AM	Why Is Myriad (MYGN) Down 6.5% Since Last Earnings Report? Zacks +5.83%
Mar-24-21 06:05PM	Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan GlobeNewswire
Mar-23-21 09:00PM	MYRIAD GENETICS ALERT: Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the Firm Business Wire -6.33%
Mar-05-21 10:03AM	Myriad Genetics (MYGN) Collaborates to Advance Oncology Care Zacks
Mar-02-21 07:05AM	Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services GlobeNewswire -7.23%
Feb-23-21 08:30PM	Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript Motley Fool
05:10PM	Recap: Myriad Genetics Q2 Earnings Benzinga
04:05PM	Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan GlobeNewswire
02:30PM	Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:14AM	A Preview Of Myriad Genetics's Earnings Benzinga
Feb-18-21 04:12PM	Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives GlobeNewswire
Feb-16-21 04:05PM	Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 GlobeNewswire
Feb-12-21 07:05AM	New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics Prolaris® test to Guide Treatment for Prostate Cancer GlobeNewswire
Feb-11-21 04:05PM	Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences GlobeNewswire +6.73%
Feb-10-21 11:11AM	New Study Favors Myriad Genetics' (MYGN) GeneSight Test Zacks
Feb-08-21 07:05AM	GeneSight Psychotropic Tests Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels GlobeNewswire
Feb-02-21 07:05AM	Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis GlobeNewswire
Jan-28-21 12:32PM	Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline Zacks
Jan-19-21 07:05AM	Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan GlobeNewswire
Jan-18-21 08:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-12-21 08:40AM	Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm Zacks
Jan-11-21 02:05PM	Myriad Genetics Forms Strategic Partnership with Illumina in Oncology GlobeNewswire +5.21%
Jan-08-21 07:05AM	Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® GlobeNewswire
Jan-06-21 10:20AM	Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit TheStreet.com +6.58%
Jan-05-21 04:05PM	Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations GlobeNewswire +8.33%
Jan-04-21 07:05AM	Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-20 07:05AM	New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations GlobeNewswire
Dec-09-20 11:30AM	Why Is Myriad (MYGN) Up 8.3% Since Last Earnings Report? Zacks
Nov-30-20 11:00AM	IPM Launches Innovative Program for Rheumatoid Arthritis PR Newswire
Nov-17-20 07:05AM	Suffering in Silence: Two-Thirds of Older Adults Say They Wont Treat Their Depression GlobeNewswire
Nov-16-20 07:05AM	Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China GlobeNewswire
Nov-15-20 08:00PM	Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China GlobeNewswire
Nov-11-20 07:05AM	New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis GlobeNewswire
Nov-10-20 08:25AM	Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates Zacks
Nov-09-20 09:30PM	Myriad Genetics Inc (MYGN) Q1 2021 Earnings Call Transcript Motley Fool +18.96%
03:15PM	Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
09:45AM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:00AM	Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter GlobeNewswire
Nov-04-20 07:05AM	Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020 GlobeNewswire +5.71%
Oct-26-20 12:31PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-16-20 09:05AM	German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test GlobeNewswire
Oct-15-20 07:05AM	Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests GlobeNewswire
Oct-05-20 12:11PM	Here is What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Sep-16-20 10:58AM	Insider Sells Myriad Genetics Stock Benzinga
Sep-12-20 11:30AM	Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-10-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member GlobeNewswire
Sep-03-20 06:21PM	Analyst Report: Myriad Genetics, Inc. Morningstar Research -7.42%
Aug-24-20 11:04AM	ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer Zacks
Aug-21-20 07:05AM	American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer GlobeNewswire
Aug-14-20 04:05PM	Myriad Genetics Announces Inducement Awards GlobeNewswire -5.38%
10:46AM	Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated Zacks
06:36AM	COVID-19 Pandemic Wreaks Havoc on Myriad Genetics' Fiscal Q4 Results Motley Fool
12:30AM	Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript Motley Fool
Aug-13-20 06:15PM	Myriad Genetics (MYGN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:19PM	Recap: Myriad Genetics Q4 Earnings Benzinga
04:08PM	Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors GlobeNewswire
04:07PM	Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results GlobeNewswire
Aug-12-20 11:01AM	Preview: Myriad Genetics's Earnings Benzinga +5.15%
Aug-10-20 07:05AM	New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions GlobeNewswire
Aug-06-20 07:05AM	Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020 GlobeNewswire
Aug-04-20 12:30PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-31-20 07:05AM	Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer GlobeNewswire
Jul-29-20 07:05AM	Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test GlobeNewswire
Jul-28-20 07:05AM	Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra® GlobeNewswire
Jul-22-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. GlobeNewswire
Jul-07-20 06:32PM	Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge Zacks
07:05AM	Myriad Announces New Studies Validating the Ability of Myriads riskScore® Test to Modify Breast Cancer Risk Prediction GlobeNewswire
Jul-06-20 10:04AM	Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis Zacks
07:05AM	Myriad Announces Partnership with OptraHEALTH® to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients GlobeNewswire
Jul-05-20 08:56PM	Hedge Funds Never Been Less Bullish On Myriad Genetics, Inc. (MYGN) Insider Monkey
Jul-02-20 08:46AM	Myriad Genetics Unveils New Home DNA Sample Collection Kit Zacks
Jul-01-20 07:05AM	Myriad Launches New GeneSight® Psychotropic Patient Collection Kit GlobeNewswire
Jun-29-20 11:27AM	Myriad Genetics' myPath Melanoma Proved Superior Per New Study Zacks
Jun-25-20 07:05AM	New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment GlobeNewswire
Jun-23-20 11:19AM	Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger Zacks
Jun-22-20 10:32AM	4 Toxic Stocks to Disown or Play Short to Book Profits Zacks
Jun-17-20 11:53AM	Myriad Genetics' Prolaris Receives Favorable Coverage Policies Zacks
Jun-15-20 07:05AM	Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider GlobeNewswire +5.83%
Jun-12-20 07:48PM	Edited Transcript of MYGN earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-11-20 02:22PM	Here's Why Myriad Genetics Is Tumbling Today Motley Fool -20.92%
11:24AM	Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries GlobeNewswire
Jun-09-20 10:23AM	Myriad Genetics' Test Better Predicts Drug Levels Per Study Zacks
Jun-08-20 07:05AM	New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing GlobeNewswire
Jun-05-20 09:00AM	Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses Zacks
Jun-04-20 11:31AM	Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report? Zacks
07:05AM	Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer GlobeNewswire
May-29-20 07:05AM	Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients GlobeNewswire
May-28-20 07:05AM	Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. GlobeNewswire
May-27-20 11:14AM	Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories Zacks
May-26-20 09:27AM	Dump These 4 Toxic Stocks or Sell Short for Timely Profits Zacks
07:00AM	Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study GlobeNewswire
May-20-20 08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
07:05AM	Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
May-18-20 11:55AM	Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem Zacks
May-13-20 05:26PM	Biotech ETFs to Gain From Latest Advancements in Cancer Drugs Zacks

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hart Jayne B.	Chief People Officer	Mar 29	Option Exercise	22.27	58,000	1,291,860	108,128	Mar 30 06:31 PM
Hart Jayne B.	Chief People Officer	Mar 29	Sale	30.00	58,000	1,740,000	80,128	Mar 30 06:31 PM
LANCHBURY JERRY S	Chief Scientific Officer	Feb 16	Option Exercise	18.00	80,000	1,440,000	321,020	Feb 17 06:10 PM
LANCHBURY JERRY S	Chief Scientific Officer	Feb 16	Sale	29.71	80,000	2,377,048	246,575	Feb 17 06:10 PM
Parkinson Paul	EVP Strategy and Innovation	Jan 08	Sale	25.00	11,824	295,600	76,746	Jan 11 04:40 PM
Phanstiel S. Louise	Director	Nov 11	Buy	16.62	15,000	249,336	66,790	Nov 12 08:57 AM
Ford Alexander	Chief Operating Officer	Sep 15	Sale	13.78	2,804	38,630	151,159	Sep 16 09:56 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience